(Learn more about this study)
Initial CDAS Request Approval
Jul 1, 2006
Prostate Cancer Other Factors-NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) may protect against prostate cancer by inducing apoptosis, inhibiting tumor cell proliferation and invasion, and reducing angiogenesis, in part through inhibition of the cyclooxygenase-2 enzyme. Although most epidemiologic studies suggest that NSAID use is inversely associated with prostate cancer, the magnitude and specificity of this association remain unclear. We examined aspirin and ibuprofen use in relation to prostate cancer risk among 29,356 men ages 55 to 74 who were initially screened for prostate cancer from 1993 to 2001 in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Men were followed from their first screening exam until September 30, 2002, during which 1,338 cases of prostate cancer were identified. Data on NSAID use were collected at baseline by a self-administered questionnaire.
To determine whether use of NSAIDs is associated with reduced risk of prostate cancer in a large prospective study.
David Chia (UCLA)
Gerald Andriole (Washington University)
Timothy Church (University of Minnesota)
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study.
Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW
Br. J. Cancer
. 2012 Jun; Volume 107 (Issue 1): Pages 207-14